Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
BMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) with shares down on Eli Lilly's solanezumab's failure. The analyst said the news decreases the value of aducanumab's.
Somaiya commented, "We expect BIIB shares to trade down on solanezumab's failure, as we believe another Abeta drug failure increases aducanumab's development risk. But downside likely limited (10-15% in our view) given aducanumab's better Abeta oligomer targeting and trial design (early vs. sola's mild patients). We believe positive titration data (CTAD, 12/9), supporting safe use of highest, most effective dose from P1b, are key to aducanumab's P3 success or at a minimum realizing value in an M&A."
The firm maintained an Market Perform rating and price target of $294.00
Shares of Biogen closed at $318.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB), Sobi Announce Presentation of ELOCTATE, ALPROLIX Data at ASH 2016
- Cowen Downgrades Nike (NKE) to Neutral; Sees Lower Guidance
- Stifel Boosts PT on Francesca's (FRAN) to $21; Notes Solid Start to Q4, Confident CEO Strategy
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Trader Talk
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!